Clinical trials: Fatigue Severity Scale
Spasticity, Multiple Sclerosis
One Year Extension Study To Protocol C2/5/TZ:MS-05
Open label, one year extension study to evaluate the clinical efficacy and safety of 12 mg sublingual tizanidine administered once nightly in MS patients who successfully completed Phase I/II protocol C2/5/TZ:MS-05 at the Tel…
- Trial name
- NCT00464958
- Testing
- sublingual tizanidine 12 mg
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Teva GTC